Log in Free sign up

Nuvasive (NUVA) News and press releases

News

From Benzinga Pro

NuVasive Earnings Perspective: Return On Invested Capital

According to Benzinga Pro, during Q1, NuVasive (NASDAQ:NUVA) earned $19.20 million, a 152.27% increase from the preceding quarter. NuVasive's sales decreased to $290.76 million, a 3.75% change since Q4.

4 Analysts Have This to Say About NuVasive

Analyst Ratings

Analysts have provided the following ratings for NuVasive (NASDAQ:NUVA) within the last quarter:

Morgan Stanley Maintains Equal-Weight on NuVasive, Raises Price Target to $62

News, Price Target, Analyst Ratings

Morgan Stanley maintains NuVasive (NASDAQ:NUVA) with a Equal-Weight and raises the price target from $60 to $62.

Wells Fargo Maintains Overweight on NuVasive, Raises Price Target to $62

News, Price Target, Analyst Ratings

Wells Fargo analyst Larry Biegelsen maintains NuVasive (NASDAQ:NUVA) with a Overweight and raises the price target from $58 to $62.

Needham Maintains Buy on NuVasive, Raises Price Target to $67

News, Price Target, Analyst Ratings

Needham analyst David Saxon maintains NuVasive (NASDAQ:NUVA) with a Buy and raises the price target from $64 to $67.

NuVasive Q1 Adj. EPS $0.54 Beats $0.39 Estimate, Sales $290.76M Beat $277.97M Estimate

NuVasive (NASDAQ:NUVA) reported quarterly earnings of $0.54 per share which beat the analyst consensus estimate of $0.39 by 38.46 percent. This is a 45.95 percent increase over earnings of $0.37 per share from the same

NuVasive: Q1 Earnings Insights

NuVasive (NASDAQ:NUVA) reported its Q1 earnings results on Wednesday, May 4, 2022 at 05:10 PM. Here's what investors need to know about the announcement. Earnings NuVasive beat estimated earnings by 38.46%, reporting an EPS of $0.54 versus an estimate of $0.39.

Earnings Scheduled For May 4, 2022

Earnings, News, Pre-Market Outlook, Markets

Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.

Earnings Outlook For NuVasive

NuVasive (NASDAQ:NUVA) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that NuVasive will report an earnings per share (EPS) of $0.39.

Benzinga's Top Ratings Upgrades, Downgrades For March 28, 2022

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Wells Fargo Initiates Coverage On NuVasive with Overweight Rating, Announces Price Target of $58

News, Price Target, Initiation, Analyst Ratings

Wells Fargo analyst Larry Biegelsen initiates coverage on NuVasive (NASDAQ:NUVA) with a Overweight rating and announces Price Target of $58.

Press releases

From Benzinga Pro

NuVasive Announces First Quarter 2022 Financial Results

Earnings, Press Releases

– Strong year-over-year net sales growth, driven by new product introductions and International sales –– Company raises lower end of full-year 2022 financial guidance range – SAN DIEGO, May 4, 2022 /PRNewswire/ --

NuVasive Specialized Orthopedics Surpasses 100 Peer-Reviewed Publications of the Precice System for Limb Lengthening

SAN DIEGO, April 26, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA) today announced a milestone of more than 100 peer-reviewed publications of the Precice® System (Precice) for conditions related to limb

NuVasive Simplify Cervical Disc Two-level Data Published in Journal of Neurosurgery: Spine

Peer-reviewed results from the two-level multi-center FDA Investigational Device Exemption study reiterate disc's superiority to ACDF SAN DIEGO, April 21, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader

NuVasive Announces Conference Call and Webcast of First Quarter 2022 Results

SAN DIEGO, April 20, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions,

Thoracolumbar Stabilization Devices Market 2022 Industry Insights, Major Key Players, And Current Trends Analysis To 2028

New York, United States, Thu, 24 Mar 2022 08:42:27 / Comserve Inc. / -- Top Key Players; B. Braun Melsungen AG, Zimmer Biomet Holdings Inc. (NYSE:ZBH), NuVasive, Inc.

Cervical Spine Surgery Market Analysis Growth Challenges, Opportunities And Future Developments To 2029

New York, United States, Sat, 12 Mar 2022 12:54:24 / Comserve Inc. / -- Top Key Company Profile;Medtronic PLC (NYSE:MDT), DePuy Synthes, Stryker Corporation (NYSE:SYK), NuVasive, Inc. (NASDAQ:NUVA), Zimmer Biomet